Nishant Tiwari Reports Zero Relapses with Scheduled Rituximab in TTP
Nishant Rajendra Tiwari, Hematology-Oncology Fellow at OU Health Stephenson Cancer Center, posted on X:
”Pre-emptive rituximab stopped relapses in our iTTP patients.
After 3-5 prior relapses each and 1 exacerbation, 4 patients received scheduled Rituximab for 2 years.
Result? No relapses during a median 17.5-month follow-up. (Range 3 – 68 months)
This is a big deal for a tough disease. Grateful to my mentor, Dr. Khawandanah and our team. More studies are needed, but hope is here.
Super thankful to all of our mentor – Dr James N George, truly a difference maker in these patients, and in his mentees’ careers.
The fellows at OU Health Stephenson Cancer Center continue to shine; we have the best leadership and the fellowship program director (Dr. Sami Ibrahimi).”
Keep up with Hemostasis Today.
-
Jan 30, 2026, 11:38Aaron Rodriguez Calienes on Intracranial Stenting: Rescue vs First-Line Outcomes
-
Jan 30, 2026, 11:25Ahmed Nasreldein on Sex Disparities in Thrombolysis Delay Among Egyptian Stroke Patients
-
Jan 30, 2026, 11:17Yanki Yarman: My PhD Project Has Been Published in Blood!
-
Jan 30, 2026, 11:08Alexandros Apostolou on Complications Associated with IDU and Thrombophilia
-
Jan 30, 2026, 10:57Peisong Ma on GRK5 Polymorphism Affecting Platelets
-
Jan 30, 2026, 10:47Ashok Yadav Explains Fetal Thrombotic Vasculopathy: FTV
-
Jan 30, 2026, 10:34Saif ur Rahman Compares K2 and K3 EDTA: Key Differences Explained
-
Jan 30, 2026, 10:22Manpreet Gill on Heparin Resistance: When 14 Years of Experience Finally Gets a Plot Twist
-
Jan 30, 2026, 10:14Mohamed Elsaid on The Role of Hyperlipidemia in Thrombogenesis